Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α,25- dihydroxyvitamin D3

Molecular Pharmacology

Volumn 51, Issue 5, 1997, Pages 741-754

  Schmiedlin Ren, Phyllissa ^a   Thummel, Kenneth E ^b   Fisher, Jeannine M ^b   Paine, Mary F ^b   Lown, Kenneth S ^a   Watkins, Paul B ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYTOCHROME P450;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; ENZYME REGULATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

EID: 0030945754     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.5.741     Document Type: Article

References (70)

1. Shimada, T., and F. P. Guengerich. Evidence for cytochrome P450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. USA 86:462-465 (1989).
2. Watkins, P. B., S. A. Wrighton, E. G. Schuetz, D. T. Molowa, and P. S. Guzelian. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80:1029-1036 (1987).
3. Kolars, J. C., P. Schmiedlin-Ren, J. D. Schuetz, C. Fang, and P. B. Watkins. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90:1871-1878 (1992).
4. Guengerich, F. P. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol. Lett. 70:133-138 (1994).
5. Kolars, J. C., W. M. Awni, R. M. Merion, and P. B. Watkins. First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490 (1991).
6. Hebert, M. F., J. P. Roberts, T. Prueksaritanont, and L. Z. Benet. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52:453-457 (1992).
7. Gomez, D. Y., V. J. Wacher, S. J. Tomlanovich, M. F. Hebert, and L. Z. Benet. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 58:15-19 (1995).
8. Thummel, K. E., D. O'Shea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, and G. R. Wilkinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:491-502 (1996).
9. Paine, M. F., D. D. Shen, K. L. Kunze, J. D. Perkins, C. L. Marsh, J. P. McVicar, D. M. Barr, B. S. Gillies, and K. E. Thummel. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60: 14-24 (1996).
10. Pinto, M., S. Rubine-Leon, M.-D. Appay, M. Kedinger, N. Triadou, E. Dussaulx, B. LaCroix, P. Simon-Assmann, K. Haffen, J. Fogh, and A. Zweibaum. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 47:323-330 (1983).
11. Hidalgo, I. J., T. J. Raub, and R. T. Borchardt. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749 (1989).
12. Wilson, G., I. F. Hassan, C. J. Dix, I. Williamson, R. Shah, M. Mackay, and P. Artursson. Transport and permeability properties of human Caco-2 cells: an in vitro model of the intestinal epithelial cell barrier. J. Control. Rel. 11:25-40 (1990).
13. Karlsson, J., S.-M. Kuo, J. Ziemniak, and P. Artursson. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1009-1016 (1993).
14. Hunter, J., M. A. Jepson, T. Tsuruo, N. L. Simmons, and B. H. Hirst. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268:14991-14997 (1993).
15. Augustijns, P. F., T. P. Bradshaw, L.-S. L. Gan, R. W. Hendren, and D. R. Thakker. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:360-365 (1993).
16. Thwaites, D. T., M. Cavet, B. H. Hirst, and N. L. Simmons. Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 114:981-986 (1995).
17. Carriere, V., T. Lesuffleur, A. Barbat, M. Rousset, E. Dussaulx, P. Costet, I. deWaziers, P. Beaune, and A. Zweibaum. Expression of cytochrome P-450 3A in HT29-MTX cells and Caco-2 clone TC7 [Published erratum in FEBS Lett. 362:99 (1995).] FEBS Lett. 355:247-250 (1994).
18. Gan, L.-S. L., M. A. Moseley, B. Khosla, P. F. Augustijns, T. P. Bradshaw, R. W. Hendren, and D. R. Thakker. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos. 24:344-349 (1996).
19. Boulenc, X., M. Bourrie, I. Fabre, C. Roque, H. Joyeux, Y. Berger, and G. Fahre. Regulation of cytochrome P450IA1 gene expression in a human intestinal cell line, Caco-2. J. Pharmacol. Exp. Ther. 263:1471-1478 (1992).
20. Pitt, A. M., J. E. Gabriels, F. Badmington, J. McDowell, L. Gonzales, and M. E. Waugh. Cell culture on a microscopically transparent microporous membrane. Biotechniques 5:162-171 (1987).
21. Traber, M. G., H. J. Kayden, and M. J. Rindler. Polarized secretion of newly synthesized lipoproteins by the Caco-2 human intestinal cell line. J. Lipid Res. 28:1350-1363 (1987).
22. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254 (1976).
23. Lown, K. S., J. C. Kolars, K. E. Thummel, J. L. Barnett, K. L. Kunze, S. A. Wrighton, and P. B. Watkins. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab. Dispos. 22:947-955 (1994) [published erratum appears in Drug Metab. Dispos. 23(3) (1995).].
24. Beaune, P., P. Kremers, F. Letawe-Goujon, and J. E. Gielen. Monoclonal antibodies against human liver cytochrome P-450. Biochem. Pharmacol. 34:3547-3552 (1985).
25. Wrighton, S. A., W. R. Brian, M.-A. Sari, M. Iwasaki, F. P. Guengerich, J. L. Raucy, D. T. Molowa, and M. Vandenbranden. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38:207-213 (1990).
26. Cribb, A., C. Nuss, and R. Wang. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Drug Metab. Dispos. 23:671-675 (1995).
27. Lee, C. A., K. E. Thummel, T. F. Kalhorn, S. D. Nelson, and J. T. Slattery. Inhibition and activation of acetaminophen reactive metabolite formation by caffeine: roles of cytochromes P-450 IA1 and IIIA2. Drug Metab. Dispos. 19:348-353 (1991).
28. Thummel, K. E., C. A. Lee, K. L. Kunze, S. D. Nelson, and J. T. Slattery. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem. Pharmacol. 45:1563-1569 (1993).
29. Kharasch, E. D., and K. E. Thummel. Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesth. Analg. 76:1033-1039 (1993).
30. Carroll, S. L., K. A. Roth, and J. I. Gordon. Liver fatty acid-binding protein: a cellular marker for studying cellular differentiation in gut epithelial neoplasms. Gastroenterology 99:1727-1735 (1990).
31. Chomczynski, P., and N. Sacchi. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159 (1987).
32. Schmiedlin-Ren, P., P. E. Benedict, W. O. III Dobbins, M. Ghosh, J. C. Kolars, and P. B. Watkins. Cultured adult rat jejunal explants as a model for studying regulation of CYP3A. Biochem. Pharmacol. 46:905-918 (1993).
33. Kolars, J. C., K. S. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S. A. Wrighton, R. M. Merion, and P. B. Watkins. CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259 (1994).
34. Chen, C., D. Clark, K. Ueda, I. Pastan, M. M. Gottesman, and I. B. Roninson. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J. Biol. Chem. 265:506-514 (1990).
35. Sweetser, D. A., E. H. Birkenmeier, I. J. Klisak, S. Zollman, R. S. Sparkes, T. Mohandas, A. J. Lusis, and J. I. Gordon. The human and rodent intestinal fatty acid binding protein genes. J. Biol. Chem. 262:16060-16071 (1987).
36. Arpin, M., E. Pringault, J. Finidori, A. Garcia, J.-M. Jeltsch, J. Vandekerckhove, and D. Louvard. Sequence of human villin: a large duplicated domain homologous with other actin-severing proteins and a unique small carboxy-terminal domain related to villin specificity. J. Cell Biol. 107: 1759-1766 (1988).
37. Pringault, E., S. Robine, and D. Louvard. Structure of the human villin gene. Proc. Natl. Acad. Sci. USA 88:10811-10815 (1991).
38. Hashimoto, H., K. Toide, R. Kitamura, M. Fujita, S. Tagawa, S. Itoh, and T. Kamataki. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem. 218:585-595 (1993).
39. Itoh, S., T. Yanagimoto, S. Tagawa, H. Hashimoto, R. Kitamura, Y. Nakajima, T. Okochi, S. Fujimoto, J. Uchino, and T. Kamataki. Genomic organization of human fetal specific P-450 IIIA7 (cytochrome P-450HFLa)-related gene(s) and interaction of transcriptional regulatory factor with its DNA element in the 5′ flanking region. Biochim. Biophys. Acta 1130:133-138 (1992).
40. Sanger, F., S. Nicklen, and A. R. Coulson. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977).
41. Becker-Andre, M., and K. Hahlbrock. Absolute mRNA quantification using the polymerase chain reaction (PCR): a novel approach by a PCR aided transcript titration assay (PATTY). Nucleic Acids Res. 17:9437-9446 (1989).
42. Gilliland, G., S. Perrin, K. Blanchard, and H. F. Bunn. Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction. Proc. Natl. Acad. Sci. USA 87:2725-2729 (1990).
43. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
44. Nelson, D. R., L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, and D. W. Nebert. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42 (1996).
45. Kronbach, T., D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36:89-96 (1989).
46. Wacher, V. J., C.-Y. Wu, and L. Z. Benet. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13:129-134 (1995).
47. Schuetz, E. G., W. T. Beck, and J. D. Schuetz. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49:311-318 (1996).
48. Halline, A. G., N. O. Davidson, S. F. Skarosi, M. D. Sitrin, C. Tietze, D. H. Alpers, and T. A. Brasitus. Effects of 1,25-dihydroxyvitamin D3 on proliferation and differentiation of Caco-2 cells. Endocrinology 134:1710-1717 (1994).
49. Gorski, J. C., S. D. Hall, D. R. Jones, M. Vandenbranden, and S. A. Wrighton. Regioselective biotransformation of midazolam by members of the human P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47:1643-1653 (1994).
50. Schuetz, J. D., and E. G. Schuetz. Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes. Cell Growth Differ. 4:31-40 (1993).
51. Prueksaritanont, T., L. M. Gorham, J. H. Hochman, L. O. Tran, and K. P. Vyas. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab. Dispos. 24:634-642 (1996).
52. Levin, M. S., V. D. Talkad, J. I. Gordon, and W. F. Stenson. Trafficking of exogenous fatty acids within Caco-2 cells. J. Lipid Res. 33:9-19 (1992).
53. Walters, M. W. Newly identified actions of the vitamin D endocrine system. Endocr. Rev. 13:719-764 (1992).
54. 3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J. Steroid Biochem. Mol. Biol. 41:231-240 (1992).
55. Adams, J. C., and F. M. Watt. Regulation of development and differentiation by the extracellular matrix. Development 117:1183-1198 (1993).
56. Basson, M. D., G. Turowski, and N. J. Emenaker. Regulation of human (Caco-2) intestinal epithelial cell differentiation by extracellular matrix proteins. Exp. Cell Res. 225:301-305 (1996).
57. Wagner, R. D., E. S. Krul, J. B. Moberly, D. H. Alpers, and G. Schonfeld. Apolipoprotein expression and cellular differentiation in Caco-2 intestinal cells. Am. J. Physiol. 263 (2 Part 1) :E374-E382 (1992).
58. Giuliano, A. R., R. T. Franceschi, and R. J. Wood. Characterization of the vitamin D receptor from the Caco-2 human colon carcinoma cell line: effect of cellular differentiation. Arch. Biochem. Biophys. 285:261-269 (1991).
59. Chen, K.-S., and H. F. DeLuca. Cloning of the human 1alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim. Biophys. Acta 1263:1-9 (1995).
60. Ozono, K., J. Liao, S. A. Kerner, R. A. Scott, and J. W. Pike. The vitamin D-responsive element in the human osteocalcin gene. J. Biol. Chem. 265: 21881-21888 (1990).
61. Kerner, S. A., R. A. Scott, and J. W. Pike. Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. Proc. Natl. Acad. Sci. USA 86:4455-1459 (1989).
62. Morrison, N. A., J. Shine, J.-C. Fragonas, V. Verkest, M. L. McMenemy, and J. A. Eisman. 1,25-Dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science (Washington D. C.) 246:1158-1161 (1989).
63. Demay, M. B., M. S. Kiernan, H. F. DeLuca, and H. M. Kronenberg. Sequences in the human parathyroid gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 89:8097-8101 (1992).
64. Huss, J. M., S. I. Wang, A. Astrom, P. McQuiddy, and C. B. Kasper. Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. Proc. Natl. Acad. Sci. USA 93:4666-4670 (1996).
65. Barwick, J. L., L. C. Quattrochi, A. S. Mills, C. Potenza, R. H. Tukey, and P. S. Guzelian. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Mol. Pharmacol. 50:10-16 (1996).
66. Deleted in proof.
67. Collington, G. K., J. Hunter, C. N. Allen, N. L. Simmons, and B. H. Hirst. Polarized efflux of 2′,7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein from cultured epithelial cell monolayers. Biochem. Pharmacol. 44:417-424 (1992).
68. Pichard, L., I. Fabre, G. Fabre, J. Domergue, B. Saint Aubert, G. Mourad, and P. Maurel. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18: 595-606 (1990).
69. Holmans, P. L., M. S. Shet, C. A. Martin-Wixtrom, C. W. Fisher, and R. W. Estabrook. The high-level expression in Escherichia coli of the membrane-bound form of human and rat cytochrome b5 and studies on their mechanism and function. Arch. Biochem. Biophys. 312:554-565 (1994).
70. Vergeres, G., and L. Waskell. Expression of cytochrome b5 in yeast and characterization of mutants of the membrane-anchoring domain. J. Biol. Chem. 267:12583-12591 (1992).